The 2026 carbidopa/levodopa update is mainly about safety monitoring and newer delivery methods, not evidence that the treatment slows Parkinson's disease. Carbidopa/levodopa—a combination that helps levodopa reach the brain—remains the preferred initial dopaminergic treatment for motor symptoms. The most urgent change is an FDA warning about vitamin-B6 deficiency and associated seizures. Meanwhile, extended-release capsules and continuous infusion may reduce "Off" time or dosing frequency, but each carries important limits and trade-offs.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Why levodopa remains the starting point
- The new vitamin-B6 warning
- What Crexont changes
- Who might consider continuous infusion
- What remains unanswered
Why levodopa remains the starting point
The American Academy of Neurology guideline, reaffirmed February 8, 2025, recommends levodopa when people with early Parkinson's disease seek treatment for motor symptoms. It advises using the lowest effective dose to limit dyskinesia and other adverse effects, according to the AAN guideline. This recommendation does not mean every patient needs the same formulation, dose, or schedule.
Treatment decisions still depend on symptom control, adverse effects, dose timing, and how much "Off" time disrupts daily life. The practical goal is adequate motor control without automatically increasing exposure. Newer products change how carbidopa/levodopa is delivered; they do not replace careful dose adjustment.
The new vitamin-B6 warning
In March 2026, the FDA required class-wide labeling warning that carbidopa/levodopa products can cause vitamin-B6 deficiency and associated seizures. The agency advises checking B6 before treatment and periodically afterward, especially with higher doses, as described in the FDA safety communication. The FDA identified 14 linked seizure cases: 13 postmarketing reports and one published case.
It found reasonable evidence that the medicines caused the deficiency and associated seizures. Reported seizures often resolved after B6 administration rather than conventional antiseizure drugs. patients and caregivers can use the warning to make medication reviews more specific: The evidence establishes a real safety signal, but 14 reported cases cannot show how often the problem occurs. The warning supports testing and clinical attention, not unsupervised supplement or medication changes.
- Ask whether a baseline B6 result is available.
- Confirm when periodic testing should occur.
- Revisit monitoring when the carbidopa/levodopa dose rises.
- If a seizure occurs, ensure the treating team knows about the B6 warning.
What Crexont changes
Crexont, also called IPX203, is an extended-release carbidopa/levodopa formulation for people with motor fluctuations. "Good On" time means periods when medication is working without troublesome involuntary movements. In a 13-week randomized phase-3 comparison, Crexont provided 0.53 additional hours of Good On time per day versus immediate-release treatment. Participants averaged three daily doses instead of five, according to the JAMA Neurology study.
📨 Get Free Parkinson's Guides Alerts
Free · No spam · Unsubscribe anytime
That result suggests a delivery and scheduling advantage, not disease modification. The short trial cannot establish long-term durability. Nausea occurred in 4.3% of the extended-release group versus 0.8% with immediate release; anxiety occurred in 2.7% versus 0%. For someone considering a formulation change, the central question is concrete: would fewer doses and roughly half an additional Good On hour justify the new regimen and its adverse-effect profile?.
Who might consider continuous infusion
Vyalev—continuous subcutaneous foscarbidopa/foslevodopa—was FDA-approved in October 2024 for adults with advanced Parkinson's disease and motor fluctuations. A pump delivers medication beneath the skin, avoiding reliance on repeated oral doses. The pivotal 12-week trial enrolled 141 patients who had at least 2.5 daily Off hours.
Compared with oral immediate-release carbidopa/levodopa, infusion added 1.75 hours of On time without troublesome dyskinesia and reduced Off time by 1.79 hours, according to the FDA prescribing information. Those gains came with substantial device burden. Infusion-site reactions affected 62%, infections affected 28%, and 22% discontinued because of adverse reactions. Candidate assessment therefore needs to include more than motor benefit:.
- Ability to manage a continuous pump
- Caregiver capacity when assistance is needed
- Willingness to inspect and care for infusion sites
- Tolerance for the possibility of reactions or infection
What remains unanswered
Researchers are still testing whether substantially higher carbidopa doses could extend levodopa's effect. A 2025 single-dose phase-I study included only 32 healthy young men. High-dose carbidopa was tolerable but had a limited effect on levodopa half-life.
That study did not test clinical benefit in people with Parkinson's disease. It therefore does not support increasing carbidopa simply to prolong symptom control. Trials in patients, using repeated treatment and meaningful symptom outcomes, would be needed to answer that question.
You Might Also Like
- Levodopa Decision Guide: Options, Trade-Offs, and Follow-Up
- Parkinsons Explained: What Patients and Families Should Know
- Parkinson’s Treatment Search Guide: Questions People Are Asking and Clear Answers